Abstract
Registries for rare diseases provide a tool for obtaining an overview of the clinical situation and can be used to discover points of improvement and to monitor long-term safety. Registries could also become a powerful tool to provide supporting information for marketing authorization. There is an urgent need for a pan-European or global strategy that supports consistent data. Therefore, transparency in data collection, harmonization of the database structures, and the convergence of scientific approaches are required.
Original language | English |
---|---|
Pages (from-to) | 492-501 |
Number of pages | 10 |
Journal | Clinical Pharmacology & Therapeutics |
Volume | 97 |
Issue number | 5 |
DOIs | |
Publication status | Published - 2015 |
Keywords
- Access to Information
- Database Management Systems
- Databases, Factual
- Evidence-Based Medicine
- Guidelines as Topic
- Hemophilia A
- Humans
- Registries